Bargman J M, Jones J E, Petro J M
Toronto Hospital, Western Division, Ontario, Canada.
Perit Dial Int. 1992;12(4):369-72.
To compare the bioavailability of intraperitoneal erythropoietin (EPO) administered undiluted versus diluted in 2 L of dialysis fluid.
Group 1 patients received one dose of EPO, 400 U/kg BW given with vehicle only. This dwelled for 8 hours after which 2 L of dialysate were infused. Group 2 patients received the same dose of EPO diluted in 2 L of dialysate which dwelled for 8 hours. Both groups resumed their CAPD regimen after the first 8 hours. Blood levels of EPO were measured for 24 hours in both groups.
The Home Peritoneal Dialysis Unit, Toronto Hospital, Western Division.
The participants were on CAPD for at least three months, free of peritonitis, and had no abnormalities of peritoneal transport. Three patients took part in both arms of the study, and there were 6 patients altogether in each group.
When EPO was administered undiluted, there was a greater than ninefold increase in bioavailability of the hormone as measured by the area under the curve (AUC), compared to when the same dose was diluted in 2 L of dialysis fluid.
The previous studies that reported low bioavailability of intraperitoneal EPO used the hormone diluted in dialysate. The current findings suggest that if EPO is given in the dry peritoneal cavity, the bioavailability is greatly improved and may be clinically effective. Intraperitoneal instillation may prove to be an alternative route for EPO in the peritoneal dialysis patient unable or unwilling to receive subcutaneous injections. We are currently studying the effectiveness of undiluted intraperitoneal EPO in CAPD patients.
比较未经稀释的腹腔内促红细胞生成素（EPO）与在2L透析液中稀释后的促红细胞生成素的生物利用度。
第1组患者仅接受一剂EPO，剂量为400U/kg体重，仅使用溶媒。保留8小时后，注入2L透析液。第2组患者接受相同剂量的EPO，在2L透析液中稀释后保留8小时。两组在最初8小时后恢复其持续性非卧床腹膜透析（CAPD）方案。两组均在24小时内测量EPO的血药浓度。
多伦多医院西区家庭腹膜透析科。
参与者进行CAPD至少三个月，无腹膜炎，腹膜转运无异常。三名患者参与了研究的两个组，每组共有6名患者。
与在2L透析液中稀释相同剂量的EPO相比，未经稀释给药时，通过曲线下面积（AUC）测量的该激素生物利用度增加了九倍以上。
先前报道腹腔内EPO生物利用度低的研究使用的是在透析液中稀释的激素。目前的研究结果表明，如果在干燥的腹腔内给予EPO，生物利用度会大大提高，可能具有临床疗效。对于无法或不愿接受皮下注射的腹膜透析患者，腹腔内滴注可能是EPO的一种替代给药途径。我们目前正在研究未经稀释的腹腔内EPO在CAPD患者中的有效性。
